133 related articles for article (PubMed ID: 18497982)
1. Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus.
Daigeler A; Chromik AM; Geisler A; Bulut D; Hilgert C; Krieg A; Klein-Hitpass L; Lehnhardt M; Uhl W; Mittelkötter U
Int J Oncol; 2008 Jun; 32(6):1205-20. PubMed ID: 18497982
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects in apoptosis induction by taurolidine and TRAIL in HCT-15 colon carcinoma cells.
Chromik AM; Daigeler A; Hilgert C; Bulut D; Geisler A; Liu V; Otte JM; Uhl W; Mittelkötter U
J Invest Surg; 2007; 20(6):339-48. PubMed ID: 18097875
[TBL] [Abstract][Full Text] [Related]
3. TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma.
Daigeler A; Brenzel C; Bulut D; Geisler A; Hilgert C; Lehnhardt M; Steinau HU; Flier A; Steinstraesser L; Klein-Hitpass L; Mittelkötter U; Uhl W; Chromik AM
J Exp Clin Cancer Res; 2008 Dec; 27(1):82. PubMed ID: 19077262
[TBL] [Abstract][Full Text] [Related]
4. Effects of TRAIL and taurolidine on apoptosis and proliferation in human rhabdomyosarcoma, leiomyosarcoma and epithelioid cell sarcoma.
Karlisch C; Harati K; Chromik AM; Bulut D; Klein-Hitpass L; Goertz O; Hirsch T; Lehnhardt M; Uhl W; Daigeler A
Int J Oncol; 2013 Mar; 42(3):945-56. PubMed ID: 23338823
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effects of sonoporation and taurolidin/TRAIL on apoptosis in human fibrosarcoma.
Daigeler A; Chromik AM; Haendschke K; Emmelmann S; Siepmann M; Hensel K; Schmitz G; Klein-Hitpass L; Steinau HU; Lehnhardt M; Hauser J
Ultrasound Med Biol; 2010 Nov; 36(11):1893-906. PubMed ID: 20870344
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines.
Van Geelen CM; Pennarun B; Ek WB; Le PT; Spierings DC; De Vries EG; De Jong S
Int J Oncol; 2010 Oct; 37(4):1031-41. PubMed ID: 20811726
[TBL] [Abstract][Full Text] [Related]
7. Taurolidine promotes cell apoptosis by enhancing GRIM‑19 expression in liver cancer.
Li F; Qi J; Qin C; Fu Z; Ren W
Oncol Rep; 2018 Dec; 40(6):3743-3751. PubMed ID: 30272302
[TBL] [Abstract][Full Text] [Related]
8. TRAIL and taurolidine enhance the anticancer activity of doxorubicin, trabectedin and mafosfamide in HT1080 human fibrosarcoma cells.
Harati K; Chromik AM; Bulut D; Goertz O; Hahn S; Hirsch T; Klein-Hitpass L; Lehnhardt M; Uhl W; Daigeler A
Anticancer Res; 2012 Jul; 32(7):2967-84. PubMed ID: 22753761
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma.
Kondo K; Yamasaki S; Sugie T; Teratani N; Kan T; Imamura M; Shimada Y
Int J Cancer; 2006 Jan; 118(1):230-42. PubMed ID: 16003725
[TBL] [Abstract][Full Text] [Related]
10. TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells.
Heijink DM; Jalving M; Oosterhuis D; Sloots IA; Koster R; Hollema H; Kleibeuker JH; Koornstra JJ; de Vries EG; de Jong S
J Pathol; 2011 Feb; 223(3):378-89. PubMed ID: 21171083
[TBL] [Abstract][Full Text] [Related]
11. Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma.
Kondo K; Yamasaki S; Inoue N; Sugie T; Teratani N; Kan T; Shimada Y
Surg Today; 2006; 36(11):966-74. PubMed ID: 17072716
[TBL] [Abstract][Full Text] [Related]
12. Taurolidine induces epithelial-mesenchymal transition via up-regulation of the transcription factor Snail in human pancreatic cancer cell lines.
Hotz B; Erben U; Arndt M; Buhr HJ; Hotz HG
Int J Colorectal Dis; 2014 Nov; 29(11):1339-48. PubMed ID: 25179425
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines.
Chromik AM; Daigeler A; Bulut D; Flier A; May C; Harati K; Roschinsky J; Sülberg D; Ritter PR; Mittelkötter U; Hahn SA; Uhl W
J Exp Clin Cancer Res; 2010 Mar; 29(1):21. PubMed ID: 20205945
[TBL] [Abstract][Full Text] [Related]
14. Taurolidine--a new drug with anti-tumor and anti-angiogenic effects.
Jacobi CA; Menenakos C; Braumann C
Anticancer Drugs; 2005 Oct; 16(9):917-21. PubMed ID: 16162968
[TBL] [Abstract][Full Text] [Related]
15. Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins.
Sun BS; Wang JH; Liu LL; Gong SL; Redmond HP
J Surg Oncol; 2007 Sep; 96(3):241-8. PubMed ID: 17469118
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer.
Darnowski JW; Goulette FA; Cousens LP; Chatterjee D; Calabresi P
Cancer Chemother Pharmacol; 2004 Sep; 54(3):249-58. PubMed ID: 15173956
[TBL] [Abstract][Full Text] [Related]
17. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
18. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
19. Gene expression analysis of cell death induction by taurolidine in different malignant cell lines.
Chromik AM; Hahn SA; Daigeler A; Flier A; Bulut D; May C; Harati K; Roschinsky J; Sülberg D; Weyhe D; Mittelkötter U; Uhl W
BMC Cancer; 2010 Oct; 10():595. PubMed ID: 21034493
[TBL] [Abstract][Full Text] [Related]
20. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
